vTv Therapeutics Inc. (NASDAQ:VTVT) received a $13.00 target price from equities researchers at HC Wainwright in a research note issued on Friday. The firm currently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s target price points to a potential upside of 211.75% from the company’s current price.

Separately, Zacks Investment Research upgraded shares of vTv Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, May 3rd. One research analyst has rated the stock with a sell rating and four have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $14.30.

vTv Therapeutics (NASDAQ VTVT) traded down 1.65% during trading on Friday, reaching $4.17. 7,995 shares of the company traded hands. The company’s market capitalization is $136.83 million. The firm has a 50-day moving average price of $4.73 and a 200-day moving average price of $5.35. vTv Therapeutics has a 52 week low of $4.13 and a 52 week high of $7.50.

vTv Therapeutics (NASDAQ:VTVT) last posted its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported ($0.41) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.43) by $0.02. The company had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.19 million. Analysts forecast that vTv Therapeutics will post ($1.09) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This piece was published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright law. The correct version of this piece can be accessed at https://www.americanbankingnews.com/2017/08/06/vtv-therapeutics-inc-nasdaqvtvt-pt-set-at-13-00-by-hc-wainwright.html.

A number of institutional investors have recently bought and sold shares of the company. Bank of New York Mellon Corp boosted its position in vTv Therapeutics by 6.1% in the first quarter. Bank of New York Mellon Corp now owns 22,780 shares of the biotechnology company’s stock worth $149,000 after buying an additional 1,305 shares in the last quarter. Essex Investment Management Co. LLC bought a new position in vTv Therapeutics during the first quarter worth $261,000. Renaissance Technologies LLC boosted its position in vTv Therapeutics by 24.3% in the fourth quarter. Renaissance Technologies LLC now owns 60,900 shares of the biotechnology company’s stock worth $294,000 after buying an additional 11,901 shares in the last quarter. Candriam Luxembourg S.C.A. bought a new position in vTv Therapeutics during the first quarter worth $917,000. Finally, Sphera Funds Management LTD. boosted its position in vTv Therapeutics by 50.0% in the first quarter. Sphera Funds Management LTD. now owns 300,000 shares of the biotechnology company’s stock worth $1,965,000 after buying an additional 100,000 shares in the last quarter. Institutional investors own 11.12% of the company’s stock.

vTv Therapeutics Company Profile

vTv Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer’s disease (AD) is azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial.

Receive News & Ratings for vTv Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.